Rising Cardiovascular Diseases Propel Vasodilator Market Growth Is Supporting Development Across The Vasodilators Market

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

What Increase In Market Value Is Predicted For The Vasodilators Market During The 2026–2030 Period?

The vasodilators market has experienced substantial growth in recent years. It is forecast to increase from $6.76 billion in 2025 to $7.16 billion in 2026, at a compound annual growth rate (CAGR) of 6.0%. The expansion in prior periods can be attributed to factors such as increasing cases of hypertension, the established clinical use of nitrates, growth in hospital infrastructure, a rising incidence of heart failure, and the widespread availability of oral vasodilators.

The vasodilators market is projected to experience substantial expansion over the upcoming years, with its size set to reach $8.86 billion in 2030, demonstrating a compound annual growth rate (CAGR) of 5.5%. This growth during the forecast period is primarily attributable to factors such as an aging global populace, an increasing prevalence of lifestyle-related illnesses, the proliferation of specialized cardiac centers, a heightened emphasis on timely diagnosis, and expanding availability of cardiovascular medications. Key trends anticipated in this period encompass a climbing incidence of cardiovascular diseases, a growing inclination towards combination drug therapies, a broader acceptance of generic vasodilators, an expansion of hospital-based cardiovascular care, and a greater need for long-term hypertension management.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=16565&type=smp

What Important Drivers Are Powering The Vasodilators Market Growth?

The expanding occurrence of cardiovascular diseases is anticipated to fuel the expansion of the vasodilators market in the future. Cardiovascular diseases encompass a range of conditions that impact the heart and its blood vessels, including coronary artery disease, heart failure, and stroke. The growing incidence of these diseases is largely due to escalating obesity levels, which continue to rise as a result of inadequate dietary habits and inactive lifestyles. The vasodilators market contributes to the treatment of cardiovascular diseases by relaxing blood vessels, thereby reducing blood pressure and enhancing overall blood circulation. As an illustration, in January 2024, the American Heart Association, a US-based non-profit organization, reported that the age-adjusted death rate from cardiovascular disease had climbed to 233.3 per 100,000 in 2024, representing a 4.0% increase from 224.4 per 100,000 in 2023. Consequently, the increasing prevalence of cardiovascular diseases is serving as a catalyst for the growth of the vasodilators market. The growing prevalence of inactive lifestyles is projected to stimulate the expansion of the vasodilators market moving forward. An inactive lifestyle is characterized by minimal physical movement and prolonged periods spent sitting or lying down, often involving very little exercise. This trend is escalating due to modern amenities like technology, improved transportation, and occupations that require desk work, all of which encourage extended periods of inactivity. Vasodilators find application in contexts of sedentary lifestyles to enhance blood circulation and mitigate high blood pressure, thereby reducing cardiovascular dangers. For example, in July 2023, the Office for National Statistics, a UK-based government department, indicated that over 86.5% of adults in Great Britain reported implementing changes to their lifestyles to address environmental concerns, according to survey data collected from May to June 2023. Consequently, the increased adoption of sedentary lifestyles is driving the growth of the vasodilators market.

Which Segment-Based Categories Are Covered In The Vasodilators Market?

The vasodilators market covered in this report is segmented –

1) By Type: Arterial Dilators, Venous Dilators, Mixed Dilators

2) By Drugs: Nitroglycerin, Alprostadil, Minoxidil, Sorbitrate, Other Drugs

3) By Indication: Hypertension, Angina, Heart Failure, Other Indications

4) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration

5) By End User: Hospitals, Homecare, Specialty Centers, Other End Users

Subsegments:

1) By Arterial Dilators: Calcium Channel Blockers, Nitric Oxide Donors, Potassium Channel Activators

2) By Venous Dilators: Nitrates, Nitrites, Phosphodiesterase Inhibitors (PDE5 Inhibitors)

3) By Mixed Dilators: Alpha-Adrenergic Antagonists, Angiotensin II Receptor Blockers (ARBs), ACE Inhibitors (Angiotensin-Converting Enzyme Inhibitors)

Which Trends Are Shaping The Vasodilators Market Landscape?

Companies within the vasodilators market are intensifying their efforts to create cutting-edge solutions, such as inhaled soluble guanylate cyclase (sGC) activators, aiming to enhance pulmonary blood flow and more effectively address cardiovascular conditions. Inhaled soluble guanylate cyclase (sGC) activators are medications designed to be inhaled, prompting the sGC enzyme to relax blood vessels and boost blood flow, particularly within the lungs. As an illustration, in September 2024, Roivant Sciences Ltd., a US-based biopharmaceutical and healthcare technology firm, introduced mosliciguat, a once-daily, inhaled sGC activator delivered through a dry powder inhaler (DPI), which was developed by its subsidiary Pulmovant. Mosliciguat is engineered for lung-specific delivery, activates sGC independently of heme and NO (potentially maintaining its function even under oxidative stress), and a Phase 1b “ATMOS” study demonstrated mean-max reductions in pulmonary vascular resistance (PVR) of up to ~38% among pulmonary hypertension patients. It exhibited good tolerability with minimal adverse events, and its pharmacokinetic profile supports once-daily administration due to a prolonged half-life and limited systemic exposure. Pulmovant has commenced a global Phase 2 “PHocus” trial involving approximately ~120 patients with PH-ILD to further evaluate its safety and efficacy.

Which Firms Are Competing In The Vasodilators Market?

Major companies operating in the vasodilators market are Pfizer Inc., Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AbbVie Inc., Abbott Laboratories, AstraZeneca, Bayer AG, Boehringer Ingelheim International GmbH, Merck & Co. Inc., GlaxoSmithKline plc, Eli Lilly and Company, Viatris Inc., Teva Pharmaceutical Industries Ltd., Novo Nordisk A/S, Astellas Pharma Inc., Amgen Inc., Gilead Sciences Inc., Biogen, Sun Pharmaceutical Industries Limited

Access The Complete Vasodilators Market Report:

https://www.thebusinessresearchcompany.com/report/vasodilators-global-market-report

Which Region Has The Strongest Presence In The Vasodilators Market?

North America was the largest region in the vasodilators market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the vasodilators market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Vasodilators Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=16565&type=smp

Browse Through More Reports Similar to the Global Vasodilators Market 2026, By The Business Research Company

Vasodilators Market Report 2026

https://www.thebusinessresearchcompany.com/report/vasodilators-global-market-report

Peripheral Vasodilator Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/peripheral-vasodilator-drugs-global-market-report

Vasopressin Market Report 2026

https://www.thebusinessresearchcompany.com/report/vasopressin-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795